A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus.
A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus.
复制标题
DOI：
10.1016/j.ymthe.2006.03.027
复制
发表时间：
2006-11
期刊：
影响因子：
--
通讯作者：
Dongming Zhou;A. Cun;Yan Li;Z. Xiang;H. Ertl
中科院分区：
文献类型：
--
作者：
Dongming Zhou;A. Cun;Yan Li;Z. Xiang;H. Ertl
狂犬病在所有人类病毒感染中死亡率最高，病毒可能通过气溶胶传播。目前批准的狂犬病病毒疫苗非常有效，但尚不清楚它们是否能对通过吸入传播的狂犬病病毒提供可靠的保护，吸入可以在进入嗅觉神经末梢后迅速进入中枢神经系统。在这里，我们描述了一种新的狂犬病病毒疫苗的临床前数据的基础上，重组复制缺陷型黑猩猩源腺病毒载体表达的糖蛋白的伊夫林Rokitniki Abelseth株狂犬病病毒。这种疫苗，称为AdC68rab.gp，口服后诱导持续的中枢和粘膜对狂犬病病毒的抗体反应，即使以中等剂量给药，也能完全保护人体免受吸入狂犬病病毒的感染。
Rabies has the highest fatality rate of all human viral infections and the virus could potentially be disseminated through aerosols. Currently licensed vaccines to rabies virus are highly effective but it is unknown if they would provide reliable protection to rabies virus transmitted through inhalation, which allows rapid access to the central nervous system upon entering olfactory nerve endings. Here we describe preclinical data with a novel vaccine to rabies virus based on a recombinant replication-defective chimpanzee-origin adenovirus vector expressing the glycoprotein of the Evelyn Rokitniki Abelseth strain of rabies virus. This vaccine, termed AdC68rab.gp, induces sustained central and mucosal antibody responses to rabies virus after oral application and provides complete protection against rabies virus acquired through inhalation even if given at a moderate dose.